Eurofins completes two deals while Eurofins stock trades 4.15 percent below its 52-week high

Published on 10/05/2026 at 15:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Element deal adds over USD 150 million in 2026 revenue. Eurofins stock costs EUR 75.93 on October 5, 2026 versus EUR 75.21, plus 0.96 percent.

Aquarellillustration der Altstadt und Skyline von Luxembourg mit Fluss und Brücken — Aquarellmalerei von Luxembourg symbolisiert den Sitz von Eurofins Scientific SE, ISIN FR0014000MR3, in Pastelltönen, Illustration mit AI erstellt.

Eurofins Scientific SE (ISIN FR0014000MR3) was trading at EUR 75.93 at Lang & Schwarz on October 5, 2026 at 3:30 p.m. CEST, plus 0.96 percent versus the EUR 75.21 prior close. On October 2, Eurofins confirmed the October 1 closing of its USD 400 million acquisition of Element Materials Technology's North American Life Sciences Testing Services business, while a second Eurofins release detailed the EUR 575 million MET Labs divestment.

Two deals reshape capital allocation

The Element business covers biopharmaceutical, environmental and food testing through 27 laboratories and facilities in North America. Eurofins said the operation employs approximately 750 staff and is expected to generate more than USD 150 million in annual revenue in 2026, with profitability similar to the group average.

The MET Labs sale involved an international network of laboratories with approximately 1,300 staff. Eurofins said proceeds would support debt reduction, laboratory investment, digital solutions, robotics, artificial intelligence, share buybacks and acquisitions in food, environmental, pharmaceutical and clinical testing.

Margins advance despite moderate growth

In its H1 2026 results discussion on July 23, management reported a 23.70 percent adjusted EBITDA margin and earnings per share of EUR 1.55, up 29.00 percent year over year, according to Yahoo Finance. The same discussion put organic growth at 2.70 percent and described a 2.90 percent foreign-exchange headwind in the first half.

Eurofins' investor materials retain a 24.00 percent adjusted EBITDA margin objective for fiscal 2027, leaving the H1 2026 margin 0.30 percentage points below that objective, according to Eurofins. The comparison matters because the two October transactions add capacity and sharpen the group's portfolio around laboratory testing while management continues to work toward its margin goal.

Eurofins stock stays below its high

At EUR 75.93, Eurofins stock stood 4.15 percent below its EUR 79.22 52-week high and above its EUR 54.10 low on October 5, 2026. Its market capitalization was EUR 13.2 billion, while the Lang & Schwarz quote remained 0.96 percent above the prior close rather than showing a one-day move large enough to define the news.

The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.